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se are honored to review the major original research in the
eld of interventional cardiology published in the year 2006.
iven space constraints, we have attempted to summarize
ey articles that we believe have relevance to the busy
linician. In addition, we have included late-breaking trials
resented at the American College of Cardiology (ACC),
ranscatheter Cardiovascular Therapeutics, and American
eart Association (AHA) conferences. Finally, in collabo-
ation with the Steering Committee for the ACC Innova-
ions in Intervention (I2) Summit, we also present the top
0 articles in the field for 2006.
CC/AHA/Society for Cardiovascular
ngiography and Interventions Percutaneous
oronary Intervention (PCI) Guidelines
n update of the 2002 PCI guidelines was published in
006 (1). These practice guidelines have evolved from a
eview of best practice to a quasi-legal document with
ncreasing influence with hospital credentialing committees,
ayors, Centers for Medicare and Medicaid Services, U.S.
ood and Drug Administration (FDA), and the tort bar.
ven state regulatory authorities are using this document to
ormulate hospital licensing standards. For this reason, a
areful reading of this document is essential for those
nvolved in the practice of interventional cardiology. We
ill point out particular areas that contain substantive
hanges from the 2002 report and also areas of great debate.
Certain “hot button” issues need to be highlighted.
perator and institutional volume standards continue to
onclude that patients have the best outcomes with high-
olume (75 per year) operators, in high-volume centers
400 per year) for elective procedures. Similarly for ST-
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007, accepted April 4, 2007.egment elevation myocardial infarction (STEMI), results
eem better when performed by operators who do at least 11
TEMI interventions and institutions that perform 36
TEMI procedures per year. Thus a Class III recommen-
ation exists for low-volume operators at low-volume cen-
ers. Another contentious recommendation is that elective
CI should not be done without surgical standby. With
espect to indications for intervention, an early invasive
trategy for high-risk unstable angina/non-STEMI patients
s endorsed (Class I, Level of Evidence A). Use of PCI for
TEMI is now strongly endorsed (Class I, Level of Evi-
ence A) when it is done for patients 12 h after onset of
ymptoms by experienced operators working in high-
olume centers. In addition, a door-to-balloon time (DBT)
f 90 min is endorsed as a goal. The ACC is now using
his recommendation as part of a national quality initiative.
ercutaneous coronary intervention should not be per-
ormed immediately in a nonculprit artery during STEMI
ntervention (Class III, Level of Evidence C). Ad hoc
ngioplasty is cautiously endorsed for simple lesions. Im-
ortantly, the committee stated that this procedure is not
andatory or standard and that staging interventions was
ppropriate to risk stratify, optimally prepare, and inform
he patient. Staging was especially indicated for patients
ith poor renal or left ventricular (LV) function and when
uitability for coronary artery bypass graft surgery is a
onsideration.
A portion of the guidelines will need constant updating.
or example, drug-eluting stents (DES) will constantly
volve. Pharmacotherapy is likely to evolve ever faster.
ecommendations on dosing and duration of clopidogrel
re outdated already. Use of bivalirudin could not take the
CUITY (Acute Catheterization and Urgent Intervention
riage Strategy) trial into account. For these reasons, a
evision is already being planned to update recommenda-
ions based on new trial data.
cute Myocardial Infarction (AMI)
rimary PCI versus thrombolysis. Although several trials
ave shown a benefit of primary PCI over thrombolysis,
ome have questioned whether primary PCI would be
uperior in daily practice, or when compared with pre-
ospital thrombolysis. Stenestrand et al. (2) reported a large
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July 17, 2007:270–85 The Year in Interventional Cardiologyegistry of consecutive STEMI patients representing more
han 95% of all patients admitted to Swedish coronary care
nits between 1999 and 2004, and followed up through
ecember 2005. Reperfusion therapy included primary PCI
n  7,084), pre-hospital thrombolysis (n  3,078), and
n-hospital thrombolysis (n  16,043). After adjusting for
ge and comorbidities, pre-hospital thrombolysis was supe-
ior to in-hospital thrombolysis at reducing mortality, par-
icularly in patients who presented within 2 h of symptom
nset. However, primary PCI was superior to both in-
ospital and pre-hospital thrombolysis at reducing 30-day
ortality (hazard ratio [HR] 0.61, 95% confidence interval
CI] 0.53 to 0.71; HR 0.70, 95% CI 0.58 to 0.85, respec-
ively) and 1-year mortality (HR 0.68, 95% CI 0.60 to 0.76;
R 0.81, 95% CI 0.69 to 0.94, respectively) (Fig. 1). The
enefits of primary PCI persisted regardless of treatment
elay. Moreover, primary PCI was associated with shorter
ospital stay and less reinfarction. Therefore, both ran-
omized trials and large registries continue to show the
enefit of primary PCI over thrombolysis, and call into
uestion whether primary PCI should be preferred over
hrombolysis even when the delay to the catheterization
aboratory exceeds 120 min.
CI after thrombolysis. The inherent delay in mobilizing
he catheterization laboratory for primary PCI may result in
urther myocardial necrosis and worse outcomes. The
SSENT-4 PCI trial (Assessment of Safety and Efficacy of
New Treatment Strategy With Percutaneous Coronary
ntervention) enrolled 1,667 STEMI patients with antici-
ated delay to the laboratory of 1 to 3 h and randomized
hem to primary PCI (n  838) or tenecteplase-facilitated
CI (n  829) (3). The trial was stopped short of the
nticipated 4,000 patients because of higher in-hospital
ortality in the facilitated group (6% vs. 3%, p  0.0105).
he primary end point of death, heart failure, or shock at 90
ays also was higher in the facilitated arm (19% vs. 13%, p
0.0045). Moreover, patients in the facilitated PCI arm
Figure 1 Estimated Cumulative Mortality Curves
Estimated cumulative mortality curves for patients receiving reperfusion treatment
using a Cox regression analysis including a propensity score for primary percutanead more strokes (1.8% vs. 0%, p  0.0001), reinfarction
6% vs. 4%, p  0.027), repeat target vessel revasculariza-
ions (TVRs) (7% vs. 3%, p  0.0041), and bleeding
omplications. No subgroup seemed to benefit from the
acilitated approach, including those with early infarcts (2
from symptom onset) or patients experiencing an exces-
ive delay to the catheterization laboratory (2 h delay from
andomization to balloon inflation).
Keeley et al. (4) conducted a meta-analysis of 17 trials
hat randomized 4,504 patients to facilitated PCI (with
hrombolytic agents, glycoprotein [GP] IIb/IIIa agents, or
oth) versus primary PCI. As expected, the facilitated
pproach improved initial Thrombolysis In Myocardial
nfarction (TIMI) flow grade 3 (37% vs. 15% of patients,
 0.0001), but post-PCI TIMI flow grade 3 was similar
89% vs. 88% of patients, p  0.30). Facilitated PCI was
ssociated with high rates of death (5% vs. 3%, p  0.04),
onfatal reinfarction (3% vs. 2%, p  0.006), TVR (4% vs.
%, p  0.01), hemorrhagic stroke (0.7% vs. 0.1%, p 
.0014), total stroke (1.1% vs. 0.3%, p 0.0008), and major
leeding (7% vs. 5%, p  0.01). The increased rates of
dverse events occurred exclusively in thrombolytic-
acilitated patients, whereas GPIIb/IIIa-facilitated patients
ad equivalent outcomes to those with primary PCI. A
eview article of facilitated PCI also concluded that facili-
ated PCI does not offer any advantage over primary PCI,
nd may be harmful (5). The investigators concluded that
lthough some studies comparing facilitated PCI with
hrombolytic agents alone have shown benefit, this advan-
age was likely because of the addition of PCI rather than
he combined approach.
Because of conflicting results among randomized trials
erforming rescue PCI after failed thrombolysis versus
onservative care, Patel et al. (6) published a meta-analysis
f 5 trials. They reported a 36% reduction in the risk of
eath (p  0.048), a 28% reduction in the risk of heart
ailure (p  0.06), but a trend for increased risk of
or after 2 h of symptom onset. Mortality curves are calculated
ronary intervention (PCI). Reprinted with permission from Stenestrand et al. (2).within
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The Year in Interventional Cardiology July 17, 2007:270–85hromboembolic stroke (p  0.07). These data suggest that
escue PCI be confined to patients with large infarcts, at risk
f death or heart failure, with careful catheter technique to
void embolic events.
Collet et al. (7) conducted a meta-analysis of randomized
rials comparing different PCI approaches to the manage-
ent of postlysis patients. Their report confirmed the
enefit of rescue PCI for failed thrombolysis and the harm
f facilitated PCI. In addition, they found that systematic
arly PCI after thrombolysis in trials conducted during the
stent era” showed a trend for reduced mortality (3.8% vs.
.7%, odds ratio [OR]  0.56, 95% CI 0.29 to 1.05, p 
.07) and a significant reduction in death or reinfarction
7.5% vs. 13.2%, OR  0.53, 95% CI 0.33 to 0.83, p 
.0067). This is in contrast to the “balloon era,” in which
orse outcomes were observed with PCI.
elayed PCI for persistent occlusion. Two publications
n 2006 questioned the utility of delayed PCI of a totally
ccluded vessel after STEMI. The OAT (Occluded Artery
rial) study was stopped before the 3,200-patient sample
ize was achieved because of recruitment difficulties (8). A
otal of 2,166 stable patients 3 to 28 days after MI with an
ccluded infarct artery (TIMI flow grade 0 to 1) were
andomized to receive PCI or medical therapy. Patients
ere excluded if they had post-MI angina or severe ischemia
n stress testing. Mean left ventricular ejection fraction
LVEF) was 48%, collaterals were present in 88%, and the
edian time to randomization was 8 days. The primary end
oint of death, myocardial infarction (MI), or class IV heart
ailure occurred in 17.2% of PCI patients versus 15.6% of
edical therapy patients (p  0.20). The rate of nonfatal
einfarction was nonsignificantly increased in the PCI group
6.9% vs. 5%, p  0.08), some of which (0.6%) was because
f periprocedural MI. In subgroup analysis, no group
eemed to benefit from PCI (including left anterior de-
cending artery–related infarctions), and young patients
65 years) had an increase in the primary event rate (17.0%
s. 13.2%, p  0.05).
The TOSCA-2 (Total Occlusion Study of Canada) trial
as a subgroup of 381 patients enrolled in the OAT study,
f which 332 patients underwent follow-up catheterization
t 1 year (9). Initial PCI was successful in 92%, and at 1 year
nfarct artery patency was observed in 83% of PCI-treated
atients versus 25% of medically treated patients (p 
.001). Ejection fraction increase was similar in both groups
4.2% vs. 3.5%), and there were slight but not significant
ifferences in LV volume and regional wall motion favoring
he PCI group.
Therefore, late restoration of flow did not improve LV
unction, death, reinfarction, or heart failure. Based on these
studies, interventionalists should continue to follow the
CC/AHA guidelines that do not recommend PCI in
symptomatic patients after AMI without ischemia on
tress testing.
mproving access to primary PCI. Given overwhelming
vidence from randomized trials regarding the benefits of hechanical reperfusion, there has been tremendous interest
n developing strategies to improve the availability of pri-
ary PCI. The AHA recently convened the Acute Myo-
ardial Infarction Advisory Working Group to explore
pecific recommendations and has issued a call to action to
mprove both the implementation and the timeliness of
rimary PCI for STEMI patients in the U.S. (10). One of
he major obstacles in the U.S. at present is the lack of a
oordinated system of STEMI care, such as that used for
evel I trauma patients (11). With this in mind, a report
rom the Vienna STEMI Registry is not only timely, but
lso has important implications for health care delivery (12).
fter organization of a cooperative network for STEMI
are in Vienna, there was a substantial increase in the use of
rimary PCI, as well as a decrease in the proportion of
atients not receiving any reperfusion therapy. Notably,
here was a significant decrease in overall in-hospital mor-
ality from 16% to 9.5% during the study period. Establish-
ent of similar coordinated systems of STEMI care in the
.S. will have a number of potential challenges, but clearly
eeds urgent attention to further improve AMI outcomes.
ime-to-treatment issues. Decreasing delays from patient
rrival to PCI-mediated reperfusion (DBT) has become a
omponent of institutional quality assessment by the Joint
ommission on Accreditation of Healthcare Organizations
JCAHO) and Center for Medicare and Medicaid Services
CMS). This quality measure has also been embraced by the
CC in a national DBT campaign. The year 2006 started
ith a sobering assessment of the national status of this
uality measure in the National Registry of Myocardial
nfarction (NRMI)-3 and -4 registries (13). As of 2002, the
ean DBT was 100 min in the 421 participating U.S.
ospitals, and 30% of patients were treated in 90 min.
o significant decrease in time delay had occurred from
999 to 2002, although high-volume centers did see a
ubstantial decline.
There has been some controversy regarding whether
BT independently affects survival or is merely a surrogate
or severity of illness or institutional quality. A number of
ublications shed light on this matter. Brodie et al. (14)
ssessed the impact of high-risk versus low-risk patients and
BT on long-term survival. They found that DBT strongly
ffected survival for high-risk patients presenting within 3 h
f symptom onset. Similarly, McNamara et al. (15) exam-
ned the NRMI-3 and -4 dataset and found a striking
elationship between mortality and DBT for high-risk but
ot for low-risk patients. Pinto et al. (16) further examined
he NRMI-3 and -4 dataset and found that institutions with
oth treatment options lose the advantage of PCI when
reatment delays are excessive. Curtis et al. (17) found that
ignificant decreases in time delay occurred when a pre-
ospital electrocardiogram was obtained. Although each of
hese publications discuss confounding issues such as insti-
utional PCI STEMI volume, severity of illness, and inter-
ction with time of presentation, decreasing treatment delay
as become a national priority. To this end, Bradley et al.
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July 17, 2007:270–85 The Year in Interventional Cardiology18) have examined health care organizational components
hat can decrease treatment delay. Importantly, integrated
ystems with emergency department physician, ambulance
ystem, and cardiologist coordination, as well as institu-
ional physician champions, can dramatically improve these
elays.
utcomes research. In 2006, there were several important
rticles regarding measurement of quality indicators and
ospital performance for AMI. The ACC/AHA Task
orce on Performance Measures provided a report on the
CC/AHA STEMI/non-STEMI set of performance mea-
ures (19). By design, this performance measurement set is
imilar to the 9 Core Measures for AMI implemented by
he JCAHO in 2002, but does have some notable differ-
nces. These include: 1) addition of angiotensin receptor
lockers to the angiotensin-converting enzyme inhibitor
easure; 2) use of median time to fibrinolytic therapy or
CI, instead of mean time; 3) incorporation of a 90-min
BT rather than the previous 120-min standard; and 4)
ddition of a reperfusion therapy measure.
Bradley et al. (20) provided an interesting report on the
orrelation between the JCAHO/CMS quality process
easures for AMI and hospital outcome, using data from
62 hospitals participating in the NRMI. In this analysis,
nly 3 of the core measures (timely reperfusion, aspirin at
ischarge, beta-blocker at discharge) were significantly cor-
elated (p  0.001) with risk-standardized 30-day mortality
ates, and together these measures explained only 6.0% of
ospital-level variation in the short-term mortality rates for
MI. These data suggest that additional process measures
re needed to explain more of the variation in AMI
utcomes and better reflect hospital performance. Presently
ospitals should continue to report not only the current core
easures but also short-term risk-standardized mortality
ates to provide an overall assessment of hospital quality.
Currently many PCI-capable hospitals in the U.S. offer
oth PCI and fibrinolysis for STEMI patients, however,
here has been debate whether this “selective” approach is
ppropriate in light of contemporary data regarding the
enefits of PCI. In 2006, Nallamothu et al. (21) provided a
imely and important report on the relationship between
ospital specialization for primary PCI and in-hospital
ortality. Specialization was defined as the relative propor-
ion of reperfusion-treated patients (PCI or fibrinolysis)
ho were treated with PCI. Greater specialization with
rimary PCI was associated with lower in-hospital mortality
nd shorter DBTs, and of note, this relationship seemed to
e independent of PCI volumes. These data suggest that
ospitals committed to PCI as the predominant reperfusion
trategy achieve the best outcomes, and emphasize the need
or hospitals to focus on providing primary PCI alone rather
han using a selective approach to reperfusion therapy.
Halkin et al. (22) examined the relationship between peak
reatine kinase (CK) level and clinical outcome after pri-
ary PCI in the CADILLAC (Controlled Abciximab and
evice Investigation to Lower Late Angioplasty Compli- Tations) trial. Peak CK was an independent predictor of
-year mortality and was independent of post-PCI TIMI
ow grade. Improvement in LVEF at 7 months was
nversely related to the peak CK level.
djunctive therapies and devices. Results of 3 random-
zed trials of adjunctive thrombectomy showed conflicting
esults. In the DEAR-MI (Dethrombosis to Enhance
cute Reperfusion in Myocardial Infarction) trial, use of the
anual aspiration Pronto extraction catheter (Vascular So-
utions, Minneapolis, Minnesota) was associated with a
ower incidence of distal embolization or no-reflow, im-
roved myocardial reperfusion, and a lower peak CK level
ompared with stenting without thrombectomy (23). On
he other hand, the AIMI (AngioJet Rheolytic Thrombec-
omy in Patients Undergoing Primary Angioplasty for
cute Myocardial Infarction) (24) and Kaltoft et al. (25)
tudies found no benefit from thrombectomy. In the AIMI
rial, patients treated with the AngioJet thrombectomy
atheter (Possis Medical, Minneapolis, Minnesota) had a
arger final infarct size, as well as a higher rate of major
dverse cardiac events (MACE) at 30 days (6.7% vs. 1.7%,
 0.01) (24). Some of the difference in outcome may be
xplained by the lower than expected event rate in the
ontrol arm, and some have questioned the study design
ecause angiographic evidence of thrombus was not re-
uired. In the study by Kaltoft et al. (25), there was no
ignificant difference in myocardial salvage (assessed with
estamibi single-photon emission computed tomography
maging) in patients treated with the Boston Scientific
escue catheter. Overall, these data suggest that there is no
ole for routine use of thrombectomy during primary PCI.
Results of trials evaluating pharmacologic adjuncts for
echanical reperfusion were also disappointing. In the
PEX-MI (Assessment of Pexelizumab in Acute Myocar-
ial Infarction) trial, 5,745 patients undergoing primary
CI were randomized to receive intravenous pexelizumab or
lacebo. At 30 days, there was no difference in the incidence
f 30-day mortality (4.06% for pexelizumab vs. 3.92% for
lacebo) (26). Hudson et al. (27) investigated whether
G-116800, an oral matrix metalloproteinase inhibitor,
ould improve LV remodeling after AMI evaluated with
erial echocardiography. The agent was well tolerated,
owever, at 90 days, there was no significant improvement
n LV systolic and diastolic volumes, ejection fraction, or
phericity index in patients receiving the matrix metallopro-
einase inhibitor. In another study, the amino acid
-arginine failed to improve vascular stiffness measurements
r LV function after AMI (28). One study from Japan,
owever, provided some hope in this field. In 603 subjects,
dministration of atrial natriuretic peptide was associated
ith a 14% reduction in infarct size assessed by CK release
inetics (29).
ES. Results of 2 trials evaluating DES in AMI were
ublished in 2006. In the TYPHOON (Trial to Assess the
se of the Cypher Stent in Acute Myocardial Infarction
reated With Angioplasty) study, 712 patients were ran-
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The Year in Interventional Cardiology July 17, 2007:270–85omized to undergo stenting with either a sirolimus-eluting
tent (SES) or any uncoated stent (30). The primary end
oint, target vessel failure at 1 year, was significantly
educed in the SES group (7.3% vs. 14.3%, p  0.004),
riven entirely by a decrease in the rate of TVR (5.6% vs.
3.4%, p  0.001). In contrast, the PASSION (Paclitaxel
luting Stent Versus Conventional Stent in ST-Segment
levation Myocardial Infarction) trial investigators found
nly a nonsignificant trend in favor of the paclitaxel-eluting
tent (PES) in 629 AMI patients (31). At 12 months, the
ncidence of the composite end point (death, MI, and target
esion revascularization [TLR]) was 8.8% in the PES group
nd 12.8% in the bare-metal stent (BMS) group (p 0.12).
f note, there was no significant difference in the incidence
f stent thrombosis in either study. Given the relatively
mall number of patients enrolled in these trials, the
iscordant results of the studies, and recent concerns about
ate stent thrombosis, we believe that further data are
equired to determine whether routine use of DES is safe or
eneficial in AMI patients.
ell-based cardiac repair. In 2006, there were numerous
ublications regarding cellular therapy for myocardial re-
eneration after AMI (Table 1). The REPAIR-AMI (Re-
nfusion of Enriched Progenitor Cells and Infarct Remod-
ling in Acute Myocardial Infarction) trial randomized 204
TEMI patients who had undergone successful primary
CI to receive intracoronary infusion of placebo versus bone
linical Trials of Stem Cell Therapy After Acute Myocardial Infarcti
Table 1 Clinical Trials of Stem Cell Therapy After Acute Myoca
Study Design n
Intracoronary infusion
ASTAMI (33) Randomized to intracoronary autologous
BMC or no therapy in patients with
anterior MI after PCI
100
BOOST (36) Randomized to intracoronary BMC
4.8 days after PCI or no therapy
60
Janssens (34) Randomized to intracoronary BMC 67
MAGIC Cell-3-DES (35) Randomized to intracoronary BMC or
control in acute and chronic MI
(14 days)
96
REPAIR-AMI (32) Randomized to intracoronary BMC or
placebo 3 to 7 days after successful PCI
204
G-CSF mobilization
G-CSF-STEMI (38) Randomized to G-CSF or placebo 5 days
after successful PCI
44
STEMMI (39) Randomized to G-CSF or placebo 6 days
after successful PCI
78
REVIVAL-2 (37) Randomized to G-CSF or placebo 5 days
after successful PCI
114MI  acute myocardial infarction; BMC  bone marrow cell; EF  ejection fraction; G-CSF  granulocy
yocardial infarction; MRI  magnetic resonance imaging; PCI  percutaneous coronary intervention; Sarrow-derived cells (BMC) 3 to 7 days after PCI (32).
he BMC group showed greater improvement in LVEF at
months (5.5  7.3% vs. 3.0  6.5%, p  0.01) and
eduction in the combined end point of death, reinfarction,
r revascularization at 1 year (4.0% vs. 2.3%, p 0.01). The
STAMI (Autologous Stem-Cell Transplantation in
cute Myocardial Infarction) study randomized 100 pa-
ients with anterior AMI treated with PCI to intracoronary
nfusion of BMC at a median of day 6 versus control (no
one marrow aspiration or infusion) (33). The LVEF was
ssessed at baseline and at 6 months by echocardiography,
ingle-photon emission computed tomography imaging,
nd magnetic resonance imaging. No difference was ob-
erved between the 2 treatment groups. Similarly, Janssens
t al. (34) found that intracoronary infusion of BMC (n 
3) versus placebo (n  34) resulted in a similar LVEF.
hey did note a suggestion of improved infarct size with
MC infusion, but multiple other end points were negative.
ang et al. (35) compared the effects of intracoronary stem
ell infusion versus control in acute and old (14 days) MI.
hey reported that stem cell infusion in AMI patients
mproved LVEF and remodeling compared with controls,
ut not in older infarctions. The BOOST (Bone Marrow
ransfer to Enhance ST-Elevation Infarct Regeneration)
rial reported follow-up at 18 months (36). Although bone
nfusion was associated with higher LVEF at 6 months,
blished in 2006
Infarction Published in 2006
Primary End Point Results
nction (assessed by echocardiography,
RI, and SPECT imaging)
No effect on LV function
nction by MRI A greater1 in EF was observed in
the BMC group at 6 months, but
at 18 months there was no
significant difference in EF
between the 2 groups
F by MRI No difference in EF at 4 months
between BMC and control groups
Improved regional systolic function
in BMC group
F by MRI AMI cell infusion group showed
improved LVEF compared with
controls (5.1% vs. 0.2%, p 
0.05), but no difference in old MI
subgroup
bal EF from baseline to 4 months by left
ntriculography
Significantly greater improvement
in global LVEF in BMC group at
4 months (5.5% vs. 3.0%, p  0.01)
bal and regional myocardial function at
months by MRI
No difference in LV function
tolic wall thickening at 6 months by MRI No difference in systolic wall
thickening between groups
ction of infarct size by Tc99m sestamibi
baseline and 4 to 6 months
G-CSF had no effect on infarct size,
LV function, or coronary restenosison Pu
rdial
LV fu
M
LV fu
LVE
LVE
Glo
ve
Glo
3
Sys
Redu
atte colony-stimulating factor; LV  left ventricular; LVEF  left ventricular ejection fraction; MI 
PECT  single-photon emission computed tomography.
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July 17, 2007:270–85 The Year in Interventional Cardiologyhere was a catch up in the control group resulting in no
ignificant difference by 18 months.
Because granulocyte colony-stimulating factor (G-CSF)
obilizes stem cells from the bone marrow and increases
heir numbers in the peripheral blood, many investigators
ave questioned whether G-CSF–induced circulating stem
ells would be sufficient to improve LVEF. Three trials were
ublished in 2006, all of which randomized STEMI pa-
ients treated with primary PCI to subcutaneous injections
f placebo versus G-CSF 10 /kg for 5 days (37–39). Each
tudy failed to show benefit in LV functional recovery.
Therefore, numerous reports are in conflict regarding the
fficacy of cellular therapy in AMI. These differences may be
ecause of high baseline ejection fraction, small sample size,
iming of cell infusions relative to infarction, or timing of
ollow-up imaging studies. In addition, some studies used
one marrow aspiration and others collected stem cells from
eripheral blood after G-CSF stimulation. Differences in
ell counts, cell type, and degree of homing to infarcted
yocardium may vary, all of which may play a role in study
esults.
ardiogenic shock. Long-term outcome data for patients
nrolled in the randomized SHOCK (Should We Emer-
ently Revascularize Occluded Coronaries for Cardiogenic
hock) trial were reported in 2006 (40). At a median
ollow-up of 6 years, there was a substantial improvement in
verall survival (32.8% vs. 19.6%) in those patients assigned
o early revascularization compared with intensive medical
herapy. A similar improvement in late outcome was seen
mong the 143 hospital survivors (62.4% vs. 44.4%). These
ata further reinforce the importance of an early revascular-
zation strategy in cardiogenic shock patients.
cute Coronary Syndrome (ACS)
n early invasive strategy has been shown to be superior to
onservative care with regard to decreasing recurrent isch-
mia, readmission, and revascularization. However, MI and
eath outcomes have conflicted with some studies showing
mproved and other studies showing worsened outcomes
ith an invasive strategy. Bavry et al. (41) conducted a
eta-analysis of 7 trials enrolling 8,375 patients with ACS
andomized to an early invasive strategy versus conservative
are. At a mean follow up of 2 years, the early invasive
trategy was associated with reduced mortality (4.9% vs.
.5%, risk ratio [RR]  0.75, 95% CI 0.63 to 0.90, p 
.001) and nonfatal MI (7.6% vs. 9.1%, RR 0.83, 95% CI
.72 to 0.96, p  0.012), suggesting long-term clinical
enefit.
The FRISC-II (Fragmin and Fast Revascularization
uring Instability in Coronary Disease) investigators re-
orted 5-year follow-up of 2,457 patients with non-STEMI
andomized to invasive versus conservative care (42). The
rimary end point of death and/or MI was improved in the
nvasive group (19.9% vs. 24.5%, RR  0.81, 95% CI 0.69
o 0.95, p  0.009). Myocardial infarction at 5 years was tignificantly improved (12.9% vs. 17.7%, RR  0.73, 95%
I 0.60 to 0.89, p  0.002), whereas mortality was similar
9.7% vs. 10.1%, RR  0.95, p  0.693).
The use of invasive strategies and potent antithrombotic
rugs may improve clinical outcome, but also increase the
isk of bleeding. In a pooled analysis of 34,146 patients with
CS (43), risk factors for major bleeding included age,
iabetes, stroke, low blood pressure, high serum creatinine,
nd ST changes on the presenting electrocardiogram. Major
leeding was independently associated with increased risk of
eath at 30 days (HR 5.37, 95% CI 3.97 to 7.26, p 
.0001) and between 1 and 6 months (HR 1.54, 95% CI
.01 to 2.37, p  0.047). The authors concluded that
wareness of importance of bleeding should lead to evalu-
tion of strategies to reduce bleeding and improve outcome.
The OASIS-5 (Fifth Organization to Assess Strategies in
cute Ischemic Syndromes) study randomized 20,078 pa-
ients with ACS to receive fondaparinux (2.5 mg daily)
ersus enoxaparin (1 mg/kg twice per day) for a mean of 6
ays (44). The primary end point of death, MI, or refractory
schemia at 9 days was similar between the 2 groups (5.8%
s. 5.7%). However, major bleeding at 9 days was signifi-
antly lower with fondaparinux (2.2% vs. 4.1%, p  0.001).
n addition, fondaparinux was associated with reduced
ortality at 30 and 180 days.
Gibson et al. (45) reported a trial of 857 ACS patients
andomized to one of 3 arms (eptifibatide  unfractionated
eparin, eptifibatide  enoxaparin, or bivalirudin mono-
herapy). Angiographic and clinical end points were con-
icting with bivalirudin showing improved minor bleeding
0.4% vs. 2.5%, p  0.027) and transfusion rates (0.4% vs.
.4%, p  0.001) as well as improved coronary flow reserve,
ut worse rates of post-PCI TIMI flow grade 3 (50.9% vs.
7.9%, p  0.048) and longer duration of post-PCI
schemia on Holter monitor (169 min vs. 36 min, p 
.013).
CI for Chronic Coronary Artery Disease
utcomes research. Although public reporting on quality
urrogate measures is now required by the JCAHO and
MS, the impact of collection and improvement of quality
ndicators on clinical outcomes is unknown. Moscucci et al.
46) provide fascinating and timely data from their report of
hospitals in Michigan that embarked on a quality im-
rovement project between 1998 and 2002. The investiga-
ors collected data on preprocedure aspirin use, total con-
rast dose, and postprocedure heparin use. Initially there was
ide variation between hospitals (postprocedure heparin use
aried from 15% to 74% of cases, GP receptor blockade
aried from 14% to 48%, and average total contrast varied
rom 333 to 247 ml/case). After intervention, all of these
arameters improved and institute variations were largely
liminated. Most importantly, MACE decreased from
.28% to 3.75% (p  0.0003) and overall mortality tended
o be lower (1.74% to 1.27%, p  0.06).
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The Year in Interventional Cardiology July 17, 2007:270–85Other investigators sought to determine predictors of
utcomes after PCI. Wu et al. (47) developed a risk model
o predict outcomes in the New York State database. Saw
t al. (48) showed that the presence of overt peripheral
rtery disease was associated with a higher 1-year mortality
n 9 randomized PCI trials. Whether this is an independent
ffect or reflects the worse renal function, more frequent
resence of diabetes, previous cerebrovascular accident, or
revious congestive heart failure is problematic. Suffice it to
ay that a history of peripheral artery disease must be noted
s an adverse prognostic marker for these patients.
Gyenes et al. (49) provided 7-year follow-up for 11,855 PCI
atients in the APPROACH (Alberta Provincial Project for
utcomes Assessment in Coronary Heart Disease) registry.
hey examined the impact of insignificant left main coronary
rtery disease (50% angiographic stenosis) on survival. The
nadjusted survival was slightly lower (86% vs. 88%), but was
dentical when adjusted for baseline variables.
eft main disease. There is mounting interest in random-
zed trials comparing DES versus coronary artery bypass
raft in symptomatic patients with unprotected left main
oronary artery disease. In 2006, 5 major articles reviewed
utcomes for patients treated with DES. The Scripps group
rovided sobering data on angiographic restenosis in 50
onsecutive patients treated with the Cypher SES (50).
ngiography performed at 3 and 9 months revealed reste-
osis in 42% of patients and subsequent TLR in 38% of
atients; 94% of this group had distal bifurcation disease,
nd most restenosis occurred at the ostium of the circumflex
rtery. In addition, much of the restenosis was silent,
uggesting that routine sentinel angiography needs to be
erformed in these patients.
Four other reports provided matched comparisons for
atients treated with coronary artery bypass graft or PCI
rom 2002 to 2005 (51–54). Overall, these reports suggest
o difference in mortality at 1 year. Given the retrospective,
onrandomized nature of these reports, no other definite
onclusions can be reached. These studies suggest a state of
quipoise exists and recommendations should await data
rom large prospective randomized trials (FREEDOM
Future Revascularization Evaluation in Patients With Di-
betes: Optimal Management of Multivessel Disease],
OMBAT [Comparison of Bypass Surgery Versus Angio-
lasty in Patients With Left Main Coronary Disease], and
YNTAX [SYNergy between percutaneous coronary inter-
ention with TAXus and cardiac surgery]).
ifurcation disease. Bifurcation lesions are difficult to
reat and are associated with higher angiographic and
linical complication rates, but have been excluded from
ost randomized trials. Two publications in 2006 addressed
his lesion subset. If one chooses to stent both branches, the
crush” technique may be considered for the side branch. An
bservational report of 231 patients treated with the DES
rush technique noted stent thrombosis by 9 months in
.3% (55). Restenosis of the main branch was 9.1%, and side
ranch restenosis occurred in 25.3%. Post-stent kissing salloon inflations seemed to reduce side branch restenosis.
he Nordic PCI study group (56) randomized 413 patients
ith a bifurcation lesion to stenting of the main vessel only,
ersus stenting of both branches. Stenting of both branches
esulted in longer procedure and fluoroscopy times, higher
ontrast volumes, and higher rates of cardiac enzyme eleva-
ions. Clinical follow-up showed similar MACE at 6
onths, and angiographic follow-up at 8 months showed
imilar restenosis rates. Therefore, stenting of the parent
essel with rescue PCI of the side branch (if necessary)
eemed to be the preferred strategy.
ES
omparisons of SES and PES. The multicenter REALITY
Prospective Randomized Multi-Center Head-to-Head Com-
arison of the Sirolimus-Eluting Stent [Cypher] and the
aclitaxel-Eluting Stent [Taxus]) trial randomized 1,386 pa-
ients to receive SES or PES (57). The primary end point,
n-lesion restenosis at 8 months, occurred in 9.6% of SES-
reated and 11.1% of PES-treated patients (p  0.31).
irolimus-eluting stents were associated with less late loss (0.09
m vs. 0.31 mm, p  0.001) and less restenosis at 8 months
p  0.001), but similar MACE compared with PES.
Long lesions are associated with poor outcomes after PCI.
he LONG-DES II study randomized 500 patients with long
25 mm) native coronary lesions to SES versus PES (58).
ean lesion length was 34 12 mm. In-segment restenosis at
months was lower in the SES compared with the PES group
3.3% vs. 14.6%, p  0.001). Target vessel revascularization
as lower in SES-treated patients (2.4% vs. 7.2%, p  0.012)
ith similar rates of death and MI.
In a multicenter registry conducted in Italy, 1,676 con-
ecutive patients with de novo coronary lesions were treated
ith DES (SES  992, PES  684) (59). An SES was
ssociated with a 55% reduction in TVR, with similar rates
f death or MI. Conversely, a large U.S. registry showed
imilar safety and TVR between SES-treated (n  3,873)
nd PES-treated (n  2,636) patients (60).
ate stent thrombosis. Reports have suggested that DES
ay be associated with delayed endothelialization (61,62),
ocalized hypersensitivity reactions (63), late malapposition
64), and late stent thrombosis. Late (1 to 12 months) stent
hrombosis was not readily apparent with BMS, yet was
eported to occur in 0.19% of patients in a large DES
egistry (65). In a meta-analysis of 14 trials that randomized
,675 patients to DES versus BMS (66), there was no
ifference in early (30 days) stent thrombosis (0.44% vs.
.5%, p  0.74) or late (30 days) thrombosis (0.5% vs.
.28%, p  0.22). However, among the 8 trials that
eported 1 year follow-up, “very late” (1 year) throm-
osis was noted in 0.5% of DES patients and in no BMS
atient (RR  5.02, 95% CI 1.29 to 19.52, p  0.02).
Predictors of late stent thrombosis have included stenting
f small vessels, multiple lesions, long stents, overlapping
tents, ostial or bifurcation lesions, prior brachytherapy,
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July 17, 2007:270–85 The Year in Interventional Cardiologyuboptimal stent result (underexpansion, malapposition,
esidual dissection), low ejection fraction, advanced age,
iabetes, renal failure, ACS, or premature discontinuation
f antiplatelet agents (64–68).
Pfisterer et al. (67) studied 746 patients treated with a
ES or BMS. All patients received dual antiplatelet therapy
or 6 months, after which aspirin alone was continued. At
0 days, rates of death or nonfatal MI were lower in the
ES group (2.0% vs. 4.69%, p  0.05). However, after
iscontinuation of clopidogrel at 6 months, late stent
hrombosis (2.6% vs. 1.3%) and death or nonfatal MI (4.9%
s. 1.3%) occurred more frequently in the DES group.
Similarly, Eisenstein et al. (68) reported an observational
tudy in 4,666 patients with follow-up at 6, 12, and 24
onths after stenting. In patients treated with BMS,
ontinued use of clopidogrel did not influence death or MI
ates between 6 and 24 months. Conversely, in DES
atients, extended use of clopidogrel at 6, 12, and 24
onths was associated with reduced death or death/MI
ates at all time intervals.
Spertus et al. (69) published an analysis from the PRE-
IER (Prospective Registry Evaluating Myocardial Infarc-
ion: Events and Recovery) registry of 500 patients with AMI
reated with DES. The mortality rate over the next 11
onths for those who stopped thienopyridine therapy was
.5%, compared with 0.7% in those who had not stopped
herapy (HR 9.0, p  0.0001). Factors identified with
remature discontinuation of thienopyridine therapy in-
luded older age, not having completed high school, not
eing married, not receiving discharge instructions for
edication use, not being referred for cardiac rehabilitation,
reater likelihood of having pre-existent cardiovascular dis-
ase or anemia, and avoiding health care because of cost.
he study investigators concluded that “additional patient
ducation about the rationale for and importance of con-
inuing thienopyridine treatment may be needed—
articularly for patients with less formal education.”
On December 7 to 8, 2006, the FDA convened an
dvisory Panel meeting to discuss stent thrombosis and
afety of DES (70). They concluded that there seems to be
n excess of late stent thrombosis with DES but the
agnitude is uncertain; and off-label use of DES (like
MS) is associated with increased risk compared with
n-label use. The panel recommended that future DES
tudies should have longer follow-up, enroll greater num-
ers of patients, and include stent thrombosis as a study end
oint. The Advisory Panel concurred with the ACC/AHA
uideline recommendation for 12 months of dual antiplate-
et therapy after a DES in patients who are not at high risk
f bleeding. However, they stated that a large, randomized
rial looking specifically at appropriate duration of dual
ntiplatelet therapy is needed.
ES for BMS restenosis. Treatment of bare-metal in-
tent restenosis (ISR) remains a challenge; however, recent
tudies suggest that the benefit of DES can be extended to
his patient group. In a 2-center registry, Liistro et al. (71) showed the safety and feasibility of SES implantation for
SR. In the randomized RIBS-II (Restenosis Intra-stent:
alloon Angioplasty Versus Sirolimus-Eluting Stenting)
rial, 150 patients with bare-metal ISR were randomized to
ither balloon angioplasty alone or implantation of an SES
72). At 9-month angiographic follow-up there was a
ignificantly lower incidence of recurrent restenosis in the
ES group (11% vs. 39%, p  0.001). The TAXUS-V ISR
rial compared the use of intracoronary brachytherapy (beta-
adiation) versus implantation of a PES in 396 patients with
SR (vessel diameter 2.5 to 3.75 mm, lesion length 46
m) (73). Treatment with a PES was associated with a
ignificant reduction in angiographic restenosis (14.5% vs.
1.2%, p  0.001) and ischemia-driven TVR at 9 months
20% vs. 34%, p  0.046). Dibra et al. (74) performed a
eta-analysis of 4 randomized trials evaluating use of DES
or ISR (ISAR-DESIRE [Intracoronary Stenting and An-
iographic Results: Drug-Eluting Stents for In-stent Reste-
osis], RIBS-II, SISR [Sirolimus-Eluting Stent to Treat
n-Stent Restenosis], TAXUS-V ISR). There was a marked
eduction in angiographic restenosis and TLR with DES
ompared with conventional therapy (balloon angioplasty or
rachytherapy), although no difference in the composite end
oint of death or MI was observed. In aggregate, these
tudies suggest that implantation of a DES should be
onsidered the best treatment strategy in patients with
are-metal ISR.
ew lesion subsets. Although DES improve clinical and
ngiographic outcomes compared with BMS in simple
esions, limited data exist regarding their benefit in complex
oronary lesions. The SCANDSTENT (Stenting Coronary
rteries in Nonstress/Benestent Disease) trial was a multi-
enter study conducted in Denmark and the Netherlands
hat randomized 322 patients with complex lesions (oc-
luded 36%, bifurcation 34%, ostial 22%) to SES versus
MS (75). The use of SES in complex lesions was associ-
ted with reduced restenosis (2.0% vs. 31.9%, p  0.001),
educed MACE (4.3% vs. 29.3%, p  0.001), and a trend
or less stent thrombosis at 6 months (0.6% vs. 3.1%, p 
.15). Suttorp et al. (76) randomized 200 patients with total
oronary occlusions to SES versus BMS. The SES group
ad lower rates of ISR (7% vs. 36%, p  0.001) and lower
VR and MACE. Vermeersch et al. (77) enrolled 75
atients with 96 lesions in diseased saphenous vein grafts
nd randomized them to SES versus BMS. At 6 months,
ES were associated with reduced ISR (11.3% vs. 30.6%,
 0.02) and reduced TVR (5.3% vs. 27%, p 0.012) with
imilar rates of death or MI.
Sometimes overlapping stents are required to completely
over long lesions or seal dissections. An increased risk of
I and restenosis has been reported after paclitaxel stents,
ut the safety of overlapping SES was unknown. Kereiakes
t al. (78) reviewed patients enrolled in 5 clinical trials of
ES, and compared 337 patients with SES overlap, 238
atients with BMS overlap, and 1,162 patients with single
tents. Regardless of stent type, stent overlap was associated
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The Year in Interventional Cardiology July 17, 2007:270–85ith increased restenosis. However, among overlap-stent
reated patients, SES provided marked reduction in reste-
osis compared with BMS (6.2% vs. 50.6%, p  0.001)
ith no increased risk of MI.
Long-term (2 years) follow-up after SES has been re-
orted in a 508-consecutive-patient registry of nonselected
atients (79) and in the randomized SIRIUS (Sirolimus-
luting Stent in de Novo Native Coronary Lesions) trial
80). Both studies show continued reduction in TVR
ompared with BMS, with no difference in death or MI
ates.
ew DES. The ENDEAVOR-II trial randomized 1,197
atients with a single coronary lesion to receive the Endeavor
otarolimus-eluting phosphorylcholine polymer-coated stent
ersus the same BMS (81). The Endeavor stent was superior at
educing the primary end point of target vessel failure at 9
onths (7.9% vs. 15.1%, p 0.0001) because of reductions in
LR (4.6% vs. 11.8%, p  0.0001). The rate of stent
hrombosis was not significantly different between DES and
MS (0.5% and 1.2%) respectively. Although the Endeavor
tent was associated with less restenosis (13.2% vs. 35.0%, p
.0001) and late loss (0.61 vs. 1.03 mm, p 0.001), inhibition
f intimal proliferation was less than that observed with the
vailable FDA-approved DES.
These findings were confirmed in the ENDEAVOR-III
rial, which randomized 436 patients in a 3:1 fashion to the
ndeavor stent versus an SES (82). At 8 months, angio-
raphic follow-up showed higher restenosis (11.7% vs.
.3%, p  0.04), greater late loss (0.34 vs. 0.13 mm,
 0.001), and more TLR (9.8% vs. 3.5%, p  0.04) with
he Endeavor stent compared with SES.
Concern has been expressed regarding whether the stent
olymer is responsible for some of the late inflammatory and
hrombogenic responses noted with DES. Accordingly, new
ES without a polymer or with a biodegradable polymer
re being tested. Mehilli et al. (83) randomized 450 patients
o receive a polymer-free, rapamycin-coated Yukon DES
ersus the Taxus polymer-based PES. Although no signif-
cant differences were observed between the Yukon DES
nd PES, the restenosis rates (14.2% vs. 15.5%) and in-stent
ate loss (0.48 vs. 0.48 mm) were higher than one would expect
rom other polymer based “limus” stents such as the Cypher
ES. Iofina et al. (84) treated 65 consecutive patients with the
axus polymer-based PES and compared them to 65 consec-
tive patients treated with a nonpolymer-based PES (V-Flex
lus, Cook Inc., Bloomington, Indiana). At 6-month follow-
p, the Taxus polymer-based PES was superior at reducing
ntimal proliferation as assessed by intravascular ultrasound,
ate loss assessed by angiography (0.22 mm vs. 0.74 mm,
 0.001), ISR (5% vs. 20%, p 0.001), and MACE (9% vs.
3%, p  0.03). These 2 studies suggest that with the current
tent designs, the polymer may be necessary to achieve the best
rug elution kinetics to reduce restenosis.
An abciximab-coated stent may be beneficial to reduce
tent thrombosis and restenosis (85). Ninety-six Korean
atients with AMI were randomized to the abciximab stent Hersus BMS. Follow-up catheterization at 6 months showed
educed late loss (0.39 vs. 0.88 mm, p  0.008), and
estenosis (13.9% vs. 34.3%, p  0.045). Clinical events
ere similar between the 2 groups.
Re-endothelialization promotes healing after arterial in-
ury. Novel stents coated with an integrin-binding cyclic
rg-Gly-Asp peptide (cRGD), which attracts endothelial
rogenitor cells, were developed (86). Porcine models were
sed to compare coronary implantation of cRGD stents,
olymer-only stents, and BMS. The cRGD stents were
ssociated with recruitment of endothelial progenitor cells
nd enhanced endothelial coverage at 4 weeks, and reduced
eointimal area by 12 weeks, compared with the other 2
tents. Therefore, stents coated with cRGD may prevent
tent thrombosis and reduce restenosis in the future.
djunctive Pharmacotherapy
lopidogrel. The appropriate timing and dose of clopi-
ogrel has received enormous attention. A post-hoc analysis
f the CREDO (Clopidogrel for Reduction of Events
uring Observation) study found that in patients treated
ith a 300-mg loading dose of clopidogrel compared with a
lacebo loading dose, little clinical benefit occurred unless
he loading dose was given 15 h before PCI (87).
To determine the incidence of antiplatelet “resistance,”
ev et al. (88) reported on 150 patients who received aspirin
or 1 week but not clopidogrel. Platelet aggregation was
easured at baseline and repeated 10 to 24 h after 300 mg
lopidogrel. Aspirin resistance was noted in 12.7% of
atients, and clopidogrel resistance was noted in 24%.
nterestingly, 47% of patients who were resistant to aspirin
ere also clopidogrel resistant. A small (n  103) dose
anging study found that higher doses of clopidogrel (600
nd 900 mg) resulted in a faster onset of action, greater
ntiplatelet effects, and reduced platelet activation compared
ith a 300-mg loading dose (89).
A larger study randomized 292 ACS patients to receive
00 mg versus 600 mg clopidogrel at least 12 h before PCI
90). Despite the12-h pretreatment, the antiplatelet effect
platelet aggregation and expression of P-selection) was
ignificantly greater after 600 mg clopidogrel compared with
00 mg. Moreover, a 600-mg clopidogrel loading dose was
ssociated with reduced cardiac events at 1 month (5% vs.
2% p 0.02). Hochholzer et al. (91) reported 802 patients
ndergoing elective stent placement who were pretreated
ith 600 mg clopidogrel. Platelet aggregation (to 5 mol/l
denosine diphosphate) was assessed before PCI. Platelet
ggregation above the median of 15% was associated with a
.7-fold (p  0.003) increase in 30-day MACE.
P IIb/IIIa receptor inhibitor. The ISAR (Intracoronary
tenting and Antithrombotic Regimen) study group has
een instrumental in showing the lack of benefit of GP
Ib/IIIa agents in stable angina patients who were pre-
reated with 600 mg clopidogrel several hours before PCI.owever, platelet activation occurs in unstable angina, thus
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July 17, 2007:270–85 The Year in Interventional Cardiologyhe clinical response may differ in ACS patients. The
SAR-REACT 2 (Intracoronary Stenting and Antithrom-
otic Regimen: Rapid Early Action for Coronary Treat-
ent 2) trial enrolled 2,022 patients with non-STEMI
CS undergoing PCI (92). All patients received aspirin 500
g, and clopidogrel 600 mg at least 2 h before PCI, and
ere randomized to abciximab plus heparin (70 U/kg)
ersus placebo with high-dose heparin (140 U/kg). The
rimary end point of death, MI, or urgent TVR was
educed in the abciximab group (8.9% vs. 11.9%, RR 
.75, 95% CI 0.58 to 0.97, p  0.03). There were no
ifferences in major or minor bleeding or transfusion re-
uirement. These data support the guideline recommenda-
ion to use abciximab during PCI in ACS patients, even if
retreated with clopidogrel.
A small study randomized 93 high-risk ACS patients
ndergoing PCI to 3 treatment arms: upstream tirofiban,
n-laboratory high-dose tirofiban, or in-laboratory abcix-
mab (93). The upstream GP IIb/IIIa arm was associated
ith better pre-PCI and post-PCI tissue perfusion as well as
educed troponin levels.
Bertrand et al. (94) evaluated the safety of bolus-only
bciximab and same-day discharge after uncomplicated
ransradial coronary stenting versus overnight hospitaliza-
ion with abciximab bolus and infusion. At 30 days, the
ncidence of the primary end point (death, MI, urgent
evascularization, major bleeding, repeat hospitalization,
ccess site complications, and severe thrombocytopenia) was
0.4% in the same-day group and 18.2% in the overnight
roup. These data suggest that the same-day discharge
trategy is not inferior to the standard overnight stay in
oderate-risk to high-risk patients.
ntithrombin therapy. As technical safety of PCI has
mproved, periprocedural safety has taken increasingly im-
ortant attention (95). In particular, bleeding risk and blood
ransfusion after PCI was the subject of 2 large trials
ublished in 2006. Results of both trials are summarized in
ables 2, 3, and 4. The STEEPLE (Safety and Efficacy of
noxaparin in Percutaneous Coronary Intervention Pa-
ients: An International Randomized Evaluation) trial eval-
ated the efficacy and safety of enoxaparin at 2 doses (0.5 or
.75 mg/kg) versus unfractionated heparin in 3,528 patients
ndergoing elective PCI (96). The 0.5-mg dose of enox-
parin was associated with a significantly lower incidence of
ajor or minor bleeding at 48 h, whereas the 0.75-mg
TEEPLE Trial: Clinical Outcomes at 30 Days
Table 2 STEEPLE Trial: Clinical Outcomes at 30 Days
Unfractionated Heparin
(n  1,230)
Glycoprotein IIb/IIIa receptor inhibitor 39.9%
Death 0.4%
Major bleed 2.8%
Transfusion 1.0%
TIMI major and minor bleed 2.2%Unfractionated heparin vs. 0.5-mg enoxaparin groups.
NS  not significant; TIMI  Thrombolysis In Myocardial Infarction.osage resulted in similar results to those in the unfraction-
ted heparin group. Of note, enrollment in the 0.5-mg
roup was stopped early by the Data Safety Monitoring
oard because of a slight excess of deaths (statistically
onsignificant).
The ACUITY (Acute Catheterization and Urgent Inter-
ention Triage Strategy) trial studied the safety and efficacy
f bivalirudin alone or bivalirudin with adjunctive GP
Ib/IIIa receptor inhibitor use versus heparin or enoxaparin
ith adjunctive IIb/IIIa in moderate-risk to high-risk ACS
atients (97). At 30 days, outcomes in the GP IIb/IIIa
eceptor inhibitor groups were similar. In the bivalirudin-
lone group, the rate of ischemic events was similar to the
ther groups; however, there was a significant reduction in
leeding. Among the 7,789 PCI patients, results in each of
he 3 treatment arms were congruent with those of the
verall ACUITY trial (98).
revention of restenosis. Oral rapamycin has shown
romise in observational studies to reduce restenosis after
MS implantation. In the ORAR II (Oral Treatment of
estenosis II) trial, 100 patients were randomized to receive
ral rapamycin for 14 days or no therapy after implantation
f a BMS (99). Rapamycin was well tolerated. Angiographic
ollow-up at 9 months showed a significant reduction in the
rimary end points of in-segment binary restenosis (11.6%
s. 42.8%, p  0.001) and late loss (0.66 vs. 1.13 mm, p 
.001).
ontrast Nephropathy
revention of contrast-induced nephropathy (CIN) remains
n important focus of ongoing research efforts. McCullough
t al. (100) presented a meta-analysis of 2,727 patients
nrolled in 16 studies comparing iodixanol with other
ow-osmolar contrast media. Overall there was a smaller
ncrease in serum creatinine in patients receiving iodixanol
ompared with the pooled low-osmolar contrast media
roup, especially in patients with chronic kidney disease or
hronic kidney disease with diabetes. After this meta-
nalysis was published, results from 3 additional random-
zed trials became available (Table 5). In the RECOVER
Renal Toxicity Evaluation and Comparison Between Visi-
aque and Hexabrix in Patients With Renal Insufficiency
ndergoing Coronary Angiography) study, 300 patients
ith a creatinine clearance60 ml/min were randomized to
.5 mg Enoxaparin/kg
(n  1,070)
0.75 mg Enoxaparin/kg
(n  1,228) p Value
40.5% 40.5% NS
1.0% 0.2% 0.07*
1.2% 1.2% 0.007
0.5% 0.8% NS
2.0% 1.6% NS0
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The Year in Interventional Cardiology July 17, 2007:270–85eceive iodixanol (Visipaque) or ioxaglate (Hexabrix) (101).
he incidence of CIN was significantly lower with iodixanol
ompared with ioxaglate (7.9% vs. 17.0%, p  0.021). In
ontrast, however, another smaller study (ICON [Ionic
ersus Nonionic Contrast to Obviate Worsening Nephrop-
thy After Angioplasty in Chronic Renal Failure Patients])
valuating the same contrast media found no difference in
IN (102). In the third study (CARE [Cardiac Angiogra-
hy in Renally Impaired Patients]), iodixanol and iopamidol
Isovue) were compared in 482 patients with a baseline
reatinine clearance60 ml/min (103). Again, there was no
ifference in the incidence of CIN between the low-osmolar
nd iso-osmolar agents.
tructural Heart Disease
ercutaneous aortic valve replacement. The year 2006
rought further encouraging reports and longer follow-up
eports of this technology. Cribier et al. (104) now report
ollow-up as long as 26 months for 36 patients treated with
he Cribier-Edwards valve that was deployed using an
ntegrade transmitral approach. Webb et al. (105) have
ioneered the use of the Cribier-Edwards valve in a retro-
rade approach using a flexible, steerable delivery catheter.
hey report the first 18 patients treated with the device in
ancouver. The valve area increased from 0.6 cm2 to 1.6
m2. The major drawback of the system is that a 24-F
elivery sheath is required and thus vascular access, vascular
rauma, and iliac vessel tortuosity limit the eligibility of
any elderly patients.
Grube et al. (106) presented the first clinical series of the
ore Valve System. This device is inserted retrogradely and
CUITY Trial: Clinical Outcomes at 30 Days in 13,819 Moderate-R
Table 3 ACUITY Trial: Clinical Outcomes at 30 Days in 13,819
Unfractionated Heparin or Enoxapari
Plus Glycoprotein IIb/IIIa
Receptor Inhibitor
(n  4,603)
Composite ischemia* 7.3%
Death 1.3%
Myocardial infarction 4.9%
Major bleed (not related to CABG) 5.7%
Blood transfusion 2.7%
TIMI major and minor bleed 6.6%
Death, myocardial infarction or unplanned revascularization for ischemia. †The p value for non
Bivalirudin plus glycoprotein IIb/IIIa receptor inhibitor versus bivalirudin alone.
ACS  acute coronary syndrome; CABG  coronary artery bypass graft surgery; NS  not signi
CUITY Trial: Clinical Outcomes at 30 Days in 7,789 Patients Who
Table 4 ACUITY Trial: Clinical Outcomes at 30 Days in 7,789 P
Unfractionated Heparin or Enoxapar
Plus Glycoprotein IIb/IIIa
Receptor Inhibitor
Composite ischemia 8.2%
Death 0.9%
Myocardial infarction 5.6%
Major bleed (not related to CABG) 6.8%bbreviations as in Table 3.s a self-expanding system that is deployed while patients are
n partial or complete bypass. In the 25 patients, procedural
uccess occurred in 84% of patients. Mortality occurred in
0% of patients. This outcome is not unexpected given the
igh-risk nature of the patients and the early learning
xperience of the center. Future device modifications, in-
luding an 18-F delivery system, will make this device
mplantable by an entirely percutaneous approach.
The Edwards valve also has been tested in a minimally
nvasive, transapical surgical approach. Lichtenstein et al. (107)
eported 7 patients treated in Vancouver with this technique.
his approach will be compared with the percutaneous tech-
ique in an upcoming FDA-mandated pivotal U.S. trial.
Finally, Zegdi et al. (108) describe a preclinical experi-
nce with a repositionable valve. The device is intended for
reatment of deteriorating bioprosthetic valves. Given the
arge number of bioprosthetic valves now implanted, this
evice holds great future promise.
ercutaneous mitral valve repair. This field seems to be
agging compared with percutaneous aortic valve therapy. In
006, the first clinical report of percutaneous mitral annulo-
lasty appeared. Webb et al. (109) reported on 5 patients who
ad an attempt at deployment of a coronary sinus cinching
evice. Successful deployment was achieved in 4 of 5 patients.
nfortunately, device separation at chronic follow-up in 3
atients led to cessation of the study. Rogers et al. (110)
eported a different and more radical technique for annulo-
lasty. Sheep with tachycardia mediated heart failure were
reated with an ingenious device that places an anchor in the
oronary sinus, and then a cinch is pulled through the left
trium to place tension on the anteroposterior dimension of the
High-Risk ACS Patients
erate-Risk or High-Risk ACS Patients
Bivalirudin Plus
Glycoprotein IIb/IIIa
Receptor Inhibitor
(n  4,604)
Bivalirudin Alone
(n  4,612) p Value
7.7% 7.8% 0.007†/0.01‡
1.5% 1.6% NS
5.0% 5.4% NS
5.3% 3.0% 0.001
2.6% 1.6% 0.001
6.5% 4.0% 0.001
ity comparison of heparin versus bivalirudin plus glycoprotein IIb/IIIa receptor inhibitor groups.
IMI  Thrombolysis In Myocardial Infarction.
erwent PCI
ts Who Underwent PCI
Bivalirudin Plus
Glycoprotein IIb/IIIa
Receptor Inhibitor Bivalirudin Alone p Value
9.3% 8.8% NS
1.1% 1.1% NS
6.6% 6.5% NS
7.5% 3.5% 0.0001isk or
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July 17, 2007:270–85 The Year in Interventional Cardiologyitral annulus. We need to wait human trials, but the 30-day
esults appear promising.
trial septal defect, patent foramen ovale, ventricular
eptal defect. Results of the MIST-1 (Migraine Intervention
ith STARflex Technology) trial, evaluating closure of patent
oramen ovale for migraine, were presented at the ACC
eeting (111). One hundred forty-seven patients were ran-
omized to closure with the STARflex device (NMT Medical,
oston, Massachusetts) or to a sham procedure. There was no
ignificant difference in the incidence of headache cessation
the primary end point); however, there was a lower incidence
f headache frequency in patients undergoing closure. Mullen
t al. (112) described use of a novel bioabsorbable device for
losure of atrial septal defects and patient foramen ovale.
uccessful device implantation was achieved in 57 of 58 (98%)
atients. At 6 months, 96% of patients had complete closure by
chocardiography. In another study, Vida et al. (113) report on
he cost effectiveness of percutaneous versus surgical closure of
stium secundum defects in 111 patients in Guatemala. In this
opulation, percutaneous closure was associated with higher
osts than surgical closure, largely because of cost of the device
tself.
Fu et al. (114) presented results of a phase I safety and
easibility trial of transcatheter closure of perimembranous
entricular septal defects using the Amplatzer Membranous
SD Occluder (AGA Medical Corp., Golden Valley,
innesota). The median age of patients was 7.7 years
range 1.2 to 54.4 years). The device was implanted suc-
essfully in 32 of 35 (91%) patients. Three patients had
erious adverse events including complete heart block,
erihepatic bleeding, and rupture of tricuspid chordae ten-
ineae. At 1 and 6 months, complete closure was observed
n 78% and 96% of patients, respectively.
eripheral Vascular Disease
CC/AHA guidelines. In 2006, guidelines for the diag-
osis and treatment of peripheral artery disease were pub-
ished for the first time (115). This consensus document was
ndorsed by multiple medical, surgical, and radiologic soci-
ties and will serve as an important quality assurance,
redentialing, and appropriateness standard. The complete
ocument is beyond the scope of this article, so readers are
ncouraged to examine the document carefully. In addition,
rials Comparing Contrast Media for Prevention of Contrast-Induce
Table 5 Trials Comparing Contrast Media for Prevention of Con
Study Contrast Media Number of Patients/Sites
CARE* (103) Iodixanol vs. iopamidol† 466 patients
25 centers
e
A
ICON* (102) Iodixanol vs. ioxaglate† 145 patients
7 centers
S
N
RECOVER (101) Iodixanol vs. ioxaglate† 300 patients
Single center
C
Presented but not yet published. †Iodixanol (Visipaque), iopamidol (Isovue), ioxaglate (Hexabrix
CIN  contrast-induced nephropathy; GFR  glomerular filtration rate; NAC  N-acetylcysteine.hite et al. (116) provided a multidisciplinary science hdvisory statement on indications for renal arteriography at
he time of cardiac catheterization. Screening renal arteri-
graphy is considered reasonable in patients at increased risk
or atherosclerotic renal artery stenosis who are candidates
or revascularization as defined in the ACC/AHA periph-
ral arterial disease management guideline document.
arotid stenting. In 2006, 2 randomized trials and 1 large
ompany-sponsored registry provided further insight into
his controversial topic. Safian et al. (117) described 419
atients treated in a prospective clinical high-risk registry of
arotid artery stenting (CAS) performed with the Protégé
elf-expanding nitinol stent and the Spider Embolic Pro-
ection System (eV3 Inc., Plymouth, Minnesota) distal
mbolic protection system. Technical success was achieved
n 97% of cases. Thirty-day adverse events were death
1.9%), any stroke (3.3%), and MI (1%). This registry
upports that CAS is safe when performed by high-volume,
xperienced interventionalists who use distal protection.
Two randomized trials of CAS versus surgery, however,
id not corroborate this finding. In the SPACE (Secondary
revention With Antioxidants of Cardiovascular Disease in
nd-Stage Renal Disease) trial, 1,200 patients with symp-
omatic carotid artery stenosis (transient ischemic attack or
toke within 6 months) were randomized to CAS or surgery
118). The primary end point, death or ipsilateral ischemic
troke at 30 days, occurred in 6.84% of the CAS group and
.34% of the surgery group (p 0.09 for noninferiority). Of
ote, only 27% of patients in the stent group were treated
ith an embolic protection device. In the second study,
atients with symptomatic carotid stenosis (60% diameter
tenosis) were randomized to stenting or endarterectomy
119). The trial was stopped prematurely after enrollment of
27 patients because of a higher incidence of death or stroke
n the stent group (9.6% vs. 3.9%).
When reviewed in aggregate, these 3 trials provide impor-
ant insight. First, carotid stenting with distal protection is a
emanding, intricate procedure and results will vary enor-
ously depending on operator skill and experience. Thus the
REATE (Carotid Revascularization with ev3 Arterial Tech-
ology Evolution) investigators achieved a stroke rate 66%
ower than the EVA-3S (Endarterectomy versus Angioplasty
n Patients with Symptomatic Severe Carotid Stenosis) group.
econd, patients with recent symptoms are likely to have
hropathy in 2006
-Induced Nephropathy in 2006
Inclusion Criteria Results
0–60 ml/min
nts received bicarbonate
ion, NAC optional
No difference in incidence CIN
creatinine 1.5–3.0 mg/dl
tional
No difference in peak increase in serum creatinine
ne clearance 60 ml/min Lower incidence of CIN with iodixanol than
ioxaglate (7.9% vs. 17.0%, p  0.021)d Nep
trast
GFR 2
ll patie
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reatiniigher event rates than those with remote or no neurological
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vent needs to be determined, and it is possible that aggressive
djunctive medical therapy (i.e., Coumadin, aspirin, clopi-
ogrel, and statins) may lower procedural risk. Finally, it is
ikely that a role for both CAS and surgery will persist.
edically high-risk patients are more likely to benefit from the
ess-invasive CAS procedure. Conversely, anatomical features
hat make the CAS procedure difficult or lengthy would favor
surgical approach. No doubt 2007 will bring much more fuel
o this raging controversy.
ther vascular beds. Although stenting is beneficial in
ignificant renal artery stenosis, the definition of hemody-
amically significant disease has not been well clarified. In
006, De Bruyne et al. (120) provided a report on hemo-
ynamic assessment of renal artery stenosis using a pressure
onitoring guidewire. A ratio of Pd/Pa 0.90 (Pdmean
ressure distal to the renal artery stenosis, Pa  mean aortic
ressure) was associated with significant increase in plasma
enal vein renin concentration, and thus was considered as a
hreshold value for defining significant renal artery stenosis.
Zeller et al. (121) reported results of a registry using the
ilverhawk atherectomy device (FoxHollow Technologies,
edwood City, California) for treatment of femoral-
opliteal disease. Acute and 1-year outcomes in patients
ith de novo disease were comparable to historical studies
sing stenting. Silva et al. (122) published a report on the
se of stenting in 59 patients with chronic mesenteric
schemia. Stenting was associated with excellent procedural
utcomes and a low complication rate, and symptom relief
ccurred in 88% of patients.
op-Ten “Must-Read” Publishedtudi s in Interv ntional Cardiology in 2006
Table 6 Top-Ten “Must-Read” PublishedStudies in Interventional Cardiology in 2006
Acronym (Ref. No.) Title
ACUITY (97) Acute Catheterization and Urgent Intervention Triage
Strategy
ASSENT-4 PCI (3) Assessment of the Safety and Efficacy of a New Treatment
Strategy for Acute Myocardial Infarction
ENDEAVOR III (82) A Prospective, Randomized Controlled Trial of the
Medtronic Endeavor Drug (ABT-578) Eluting Coronary
Stent System Versus the Cypher Sirolimus-Eluting
Coronary Stent System in De Novo Native Coronary
Artery Lesions
ISAR-REACT 2 (92) Intracoronary Stenting and Antithrombotic Regimen: Rapid
Early Action for Coronary Treatment 2
OAT (8)* Occluded Artery Trial
REALITY (57) Randomized Multicenter Head-to-Head Comparison of the
Sirolimus-Eluting Stent (Cypher) and the Paclitaxel-
Eluting Stent (Taxus)
REPAIR-AMI (32) Reinfusion of Enriched Progenitor Cells and Infarct
Remodeling in Acute Myocardial Infarction
RIKS-HIA (2) Register of Information and Knowledge About Swedish
Heart Intensive Case Admissions
SCANDSTENT (75) Stenting of Coronary Arteries in Non-Stress/Benestent
Disease
TYPHOON (30) Trial to Assess the Use of the Cypher Stent in Acute
Myocardial Infarction Treated With Balloon AngioplastyWinner of the Innovations in Intervention (I2) Scientific Achievement Award.onclusions
he year 2006 brought forth many dramatic advances in the
eld of interventional cardiology. The Innovations in Inter-
ention (I2) steering committee has selected the 10 most
mportant published studies of 2006 (Table 6). Although
uch a list is subjective, we believe that these trials will stand
he test of time with respect to their impact on the field. As
xpected, the top-10 list is dominated by trials of mechan-
cal reperfusion for AMI and new advances with DES
latforms. The OAT trial was voted as the most important
tudy of 2006. We believe it is essential for interventionalists
nd other serious students of the field to examine these
tudies carefully. The year 2007 is likely to bring further
xciting advances in this rapidly evolving field. We look
orward to an equally daunting task of collating and sum-
arizing the trials of 2007.
eprint requests and correspondence: Dr. Simon R. Dixon, Divi-
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